Hyperuricemia and gout: New concepts in diagnosis and management

Postgraduate Medicine

Volumn 124, Issue 6, 2012, Pages 98-109

  Doghramji, Paul P ^a   Wortmann, Robert L ^b  

^a URSINUS COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Gout; Hyperuricemia; Tophus; Uric acid; Uricase

Indexed keywords

ALLOPURINOL; ASCORBIC ACID; COLCHICINE; FEBUXOSTAT; GLUCOCORTICOID; INDOMETACIN; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PREDNISONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SULINDAC; TRIAMCINOLONE ACETONIDE;

ARTICLE; CHRONIC PAIN; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; GOUT; HUMAN; HYPERURICEMIA; JOINT INJURY; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RISK FACTOR; SINGLE DRUG DOSE; WEIGHT REDUCTION; PAIN; REVIEW;

DISEASE PROGRESSION; GOUT; HUMANS; HYPERURICEMIA; PAIN;

MLCS; MLOWN;

EID: 84875791447     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.11.2616     Document Type: Article

References (96)

1. Perez-Ruiz F, Herrero-Beites AM. Evaluation and treatment of gout as a chronic disease [published online ahead of print October 25, 2012]. Adv Ther.
2. Schumacher HR Jr. The pathogenesis of gout. Cleve Clin J Med. 2008;75(suppl 5):S2-S4.
3. Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010;12(2):118-124.
4. Hamburger M, Baraf HS, Adamson TC 3rd, et al; European League Against Rheumatism. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 suppl 1):3-36.
5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141.
6. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62(6): 1576-1582.
7. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(suppl 1):S2.
8. Wortmann RL. Gout and hyperuricemia. In: Firestein GS, Budd RC, Harris ED Jr, et al, eds. Kelley's Textbook of Rheumatology. 8th ed. Volume I. Philadelphia, PA: W. B. Saunders Company; 2008:1481-1506.
9. Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008; 75(suppl 5):S9-S12.
10. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104-1110.
11. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
12. Adams PF, Hendershot GE, Marano MA; Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10. 1999;200:1-203.
13. Doghramji PP. Managing your patient with gout: a review of treatment options. Postgrad Med. 2011;123(3):56-71.
14. Wang DD, Sievenpiper JL, de Souza RJ, et al. The effects of fructose intake on serum uric acid vary among controlled dietary trials. J Nutr. 2012;142(5):916-923.
15. Zgaga L, Theodoratou E, Kyle J, et al. The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS One. 2012;7(6):e38123.
16. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3-7.
17. Lieberman JA 3rd. Treatment and prophylaxis of gout flare in the clinic: an office-based approach to gout management. Postgrad Med. 2011;123(6):151-165.
18. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48(5):582-586.
19. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33(1):104-109.
20. Becker MA, Schumacher HR Jr, Wortmann RL. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
21. Shulten P, Thomas J, Miller M, Smith M, Ahern M. The role of diet in the management of gout: a comparison of knowledge and attitudes to current evidence. J Hum Nutr Diet. 2009;22(1):3-11.
22. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46.
23. Dubchak N, Falasca GF New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis. 2010;3:145-166.
24. Singh JA, Sarkin A, Shieh M, et al. Health care utilization in patients with gout. Semin Arthritis Rheum. 2011;40(6):501-511.
25. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35(3):498-501.
26. Richette P, Bardin T Gout. Lancet. 2010;375(9711):318-328.
27. Edwards NL. Gout: clinical and laboratory features. In: Klippel JH, Crofford L, Stone JH, et al, eds. Primer on the Rheumatic Diseases. 12th ed. Atlanta, GA: Arthritis Foundation; 2001:313-319.
28. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care. 2005;11(15 suppl):S459-S464.
29. Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub RA. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012;64(2): 327-338.
30. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-1106.
31. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991-F997.
32. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269-275.
33. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18(6):526-530.
34. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342-350.
35. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50(5):973-981.
36. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-1821.
37. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118(8):816-826.
38. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther. 2011;13(2):R66.
39. Brodov Y, Chouraqui P, Goldenberg I, Boyko V, Mandelzweig L, Behar S. Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology. 2009;114(4):300-305.
40. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298-303.
41. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247-252.
42. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696.
43. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
44. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885-892.
45. Roncal CA, Reungjui S, Sánchez-Lozada LG, et al. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol. 2009;30(5):399-404.
46. Lottmann K, Chen X, Schädlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep. 2012;14(2):195-203.
47. Baraf HS, Matsumoto AK. Pegloticase: a new biologic for treating advanced gout. Int J Clin Rheumatol. 2012;7(2):143-154.
48. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006;8(suppl 1):S4.
49. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59(7):1799-1806, 1810.
50. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8(suppl 1):S3.
51. Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest. 2006;116(8):2073-2075.
52. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115.
53. Borges RL, Ribeiro AB, Zanella MT, Batista MC. Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep. 2010;12(2):113-119.
54. Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens. 1999;17(7):869-872.
55. Chen SY, Chen CL, Shen ML. Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol. 2007;26(9):1453-1457.
56. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742-748.
57. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48(suppl 2):ii2-ii8.
58. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr. 2008;87(5):1480-1487.
59. Bhole V, Choi JW, Kim SW, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010;123(10):957-961.
60. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567-1570.
61. Fraile JM, Puig JG, Torres RJ, de Miguel E, Martínez P, Vázquez JJ. Uric acid metabolism in patients with primary gout and the metabolic syndrome. Nucleosides Nucleotides Nucleic Acids. 2010;29(4-6): 330-334.
62. Gutman AB. Treatment of primary gout: the present status. Arthritis Rheum. 1965;8(5):911-920.
63. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907-1912.
64. Dalbeth N, McQueen FM. Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol. 2009;21(2): 124-131.
65. Singh JA, Taylor WJ, Simon LS, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011;38(7):1452-1457.
66. Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford). 2011;50(4): 740-745.
67. Dalbeth N, Lindsay K. The patient's experience of gout: new insights to optimize management. Curr Rheumatol Rep. 2012;14(2): 173-178.
68. Langley P, Nuki G, Forsythe A. Pain, health-related quality of life and health status in gout in Europe. Poster presented at: EULAR Annual European Congress of Rheumatology; June 6-9, 2012; Berlin, Germany. Poster FRI0387.
69. Zhang W, Doherty M, Pascual E, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10): 1301-1311.
70. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford). 2007;46(7):1116-1121.
71. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421-426.
72. Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29(9): 1950-1953.
73. Nakayama D, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum. 1984;27(4):468-471.
74. Wallace SI, Bernstein D, Diamond H. Diagnostic value of the colchicine therapeutic trial. JAMA. 1967;199(8):525-528.
75. Dalbeth N, Pool B, Gamble GD, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 2010;62(5): 1549-1556.
76. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-1103.
77. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283-289.
78. Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of the weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford). 2010;49(12):2391-2399.
79. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. J Rheumatol. 2008;35(9):1853-1858.
80. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277-1281.
81. Schumacher HR Jr, Chen LX. The practical management of gout. Cleve Clin J Med. 2008;75(suppl 5):S22-S25.
82. Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324.
83. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-1068.
84. Colcrys [package insert]. Philadelphia, PA: AR Scientific, Inc; 2012.
85. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14): 2386-2397.
86. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4): 356-360.
87. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529-2536.
88. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
89. Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11): 1540-1548.
90. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711-720.
91. Krystexxa [package insert]. East Brunswick, NJ: Savient Pharmaceuticals, Inc; 2012.
92. Crittenden DB, Pillinger MH. The year in gout-2010-2011. Bull NYU Hosp Jt Dis. 2011;69(3):257-263.
93. Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis. 2011;14(3): e33-e37.
94. Edney A. Regeneron's Arcalyst fails to win US backing for gout. Bloomberg website. http://www.bloomberg.com/news/2012-07-31/ regeneron-s-arcalyst-fails-to-win-u-s-backing-for-gout.html. Accessed November 1, 2012.
95. Burton TM. FDA panel votes against gout drug. The Wall Street Journal website. http://online.wsj.com/article/SB100014240527023048879045 76400062633107174.html. Accessed November 1, 2012.
96. McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1): 121-129.